Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 1, January-February, p. 101–108

doi: 10.17219/acem/63251

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Diagnostic usefulness of sCD163, procalcitonin and neopterin for sepsis risk assessment in critically ill patients

Agnieszka Sapa1,A,C,D,E,F, Alina Rak1,B,C,D, Magdalena Wybieralska2,B,C, Jakub Machoń3,B,C,E, Anna Krzywonos-Zawadzka1,B,E, Kamil Zawadzki3,B,C, Marek Wełna3,B, Mieczysław Woźniak1,A,F

1 Department of Clinical Chemistry, Wroclaw Medical University, Poland

2 Ziemo-Vita Public Health Care Laboratory Ltd., Wrocław, Poland

3 Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Poland


Background. Sepsis is one of the most common causes of hospitalization and it is characterized by a high mortality rate in spite of the great progress in diagnosis and treatment achieved in recent years. Early diagnosis of sepsis is one of the most important elements of effective treatment. The clinical symptoms are not specific and biomarkers are considered to be useful tools in sepsis diagnostics.
Objectives. The aim of our study was to evaluate the diagnostic value of sCD163 as a marker of sepsis and a comparison of it with procalcitonin and neopterin in ICU patients.
Material and Methods. Concentrations of PCT, sCD163 and NPT were measured in 52 serum samples collected from 30 patients of the Department of Anesthesiology and Intensive Therapy of the University Hospital in Wroclaw. Venous blood was collected on the 1st and 3rd day of hospitalization. The Human CD163 Quantikine ELISA Kit was used to determine the concentrations of sCD163. Neopterin concentrations were measured by a Neopterin ELISA kit. PCT was measured at the University Center of Laboratory Diagnostics in Wroclaw using an automatic VIDAS® B.R.A.H.M.S. PCT assay.
Results. Our study showed that there was a significant difference between the values obtained in the study and the reference group for PCT (p < 0.0001), sCD163 (p = 0.0001) and NPT (p = 0.0001), whereas there was no difference observed between the samples obtained on the 1st and 3rd day (p = 0.5129). The area under the ROC curve was 0.847, and was comparable to the AUC of procalcitonin (0.840), and slightly higher than the AUC of neopterin (0.763), although these differences were not significant (p = 0.2990 and p = 0.9329, respectively).
Conclusion. sCD163 and neopterin are promising parameters in the diagnosis of sepsis, and their value in the diagnosis of sepsis in critically ill patients may be comparable to procalcitonin.

Key words

biomarkers, sepsis, procalcitonin, sCD163, neopterin

References (28)

  1. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infec Dis. 2012;73:221–227.
  2. Lever A, Mackenzie I. Sepsis: Definition, epidemiology, and diagnosis. BMJ. 2007;335:879–883.
  3. Pierrakos C, Vincent J-L. Sepsis biomarkers: A review. Crit Care. 2010;14:R15.
  4. Hryckiewicz K, Juszczyk J, Samet A, Arłukowicz E, Śledzińska A, Bolewska B. Prokalcytonina jako marker diagnostyczny zespołu uogólnionej reakcji zapalnej (SIRS) i posocznicy. Przegl Epidemiol. 2006;60:7–15.
  5. Pourakbari B, Mamishi S, Zafari J, et al. Evaluation of procalcitonin and neopterin level in serum of patients with acute bacterial infection. Braz J Infect Dis. 2010;14:252–255.
  6. Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX. Clinical significance of soluble hemoglobin scavenger receptor CD163 (sCD163) in sepsis, a prospective study. PLoS One. 2012;7(7):e38400. doi: 10.1371/journal.pone.0038400.
  7. Su L, Feng L, Song Q, et al. Diagnostic value of dynamics serum sCD163, sTREM-1, PCT, and CRP in differentiating sepsis, severity assessment, and prognostic prediction. Mediators Inflamm. 2013. Internet: (accessed 26 June 2015).
  8. Abdelrahman RS, Wagih AA, Elbarbary AH. The diagnostic value of serum level of soluble hemoglobin scavenger receptor CD163 for sepsis in the ICU. Tanta Med J. 2015;43:9–15.
  9. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323:17–29.
  10. Dorizzi R, Polati E, Sette P, Ferrari A, Rizzotti P, Luzzani A. Procalcitonin in the diagnosis of inflammation in intensive care units. Clin Bio-chem. 2006;39:1138–1143.
  11. Sheldon J, Riches P, Soni N, et al. Plasma neopterin as an adjunct to C-reactive protein in assessment of infection. Clin Chem. 1991;37: 2038–2042.
  12. Mierzwa G, Parzęcka M, Szaflarska-Popławska A, Stefańska A, Odrowąż-Sypniewska G. Ocena przydatności klinicznej oznaczania neopteryny u dzieci i młodzieży z przewlekłym zapaleniem błony śluzowej żołądka i/lub dwunastnicy z zakażeniem i bez zakażenia Helicobacter pylori. Prz Gastroenterol. 2009;4:83–87.
  13. Shameem Banu A, Latha P, Kaveri K, Jayakumar S. Serum neopterin estimation as an indicator for safe blood transfusion. J Clin Diagn Res. 2011;5:1555–1558.
  14. Kozłowska-Murawska J, Obuchowicz A. Przydatność kliniczna oznaczania stężenia neopteryny. Wiad Lek. 2008;61:269–271.
  15. Onofre G, Koláčková M, Jankovičová K, Krejsek J. Scavenger receptor CD163 and its biological functions. Acta Medica. 2009;52:57–61.
  16. Møller H. Soluble CD163. Scand J Clin Lab Invest. 2012;72:1–13.
  17. Møller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 2002;99:378–380.
  18. Su L, Feng L, Liu C, et al. Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury: A prospective study. BMC Neph-rol. 2012;1:123. doi: 10.1186/1471-2369-13-123.
  19. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care. 1999;3:45–50.
  20. Sudhir U, Venkatachalaiah R, Kumar T, Rao M, Kempegowda P. Significance of serum procalcitonin in sepsis. Indian J Crit Care Med. 2011;15:1–5. (accessed 10 July 2015).
  21. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids. 2008;35:303–307.
  22. Fisgin N, Aliyazicioglu Y, Tanyel E, et al. The value of neopterin and procalcitonin in patients with sepsis. South Med J. 2010;103:216–219.
  23. Girgin G, Sahin T, Fuchs D, et al. Tryptophan degradation and serum neopterin concentrations in intensive care unit patients. Toxicol Mech Methods. 2011;21:231–235.
  24. Møller HJ, Moestrup SK, Weis C, et al. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med. 2006;34:2561–2566.
  25. Kjærgaard AG, Rødgaard-Hansen S, Dige A, Krog J, Møller HJ, Tønnesen E. Monocyte expression and soluble levels of the haemoglobin re-ceptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients. PLoS One. 2014;9(3):e92331. doi: 10.1371/journal.pone.0092331.
  26. Ingels C, Møller HJ, Hansen TK, Wouters PJ, Vanhorebeek I, Van den Berghe G. Circulating levels of the shed scavenger receptor sCD163 and association with outcome of critically ill patients. J Clin Immunol. 2013;33:619–629.
  27. Gaїni S, Koldkjær OG, Pedersen SS, Pedersen C, Moestrup SK, Møller HJ. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. PMIS. 2006;114:103–111.
  28. Gaïni S, Pedersen SS, Koldkaer OG, Pedersen C, Moestrup SK, Møller HJ. New immunological serum markers in bacteraemia: An-ti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis. Clin Exp Immunol. 2008;151:423–431.